# OnCo record xport-ec-042 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/xport-ec-042/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "xport-ec-042", "NCT05611931" ;
  schema:name "XPORT-EC-042 / ENGOT-EN20 / GOG-3083"@en ;
  schema:description "XPORT-EC-042 tested maintenance selinexor against placebo in TP53-normal advanced endometrial cancer after response to platinum chemotherapy, chasing a subgroup finding from the earlier SIENDO trial. It missed its primary endpoint in July 2026: a trend favoured selinexor but did not reach statistical significance, a lesson in the limits of post-hoc biomarker subgroups."@en ;
  schema:url <https://onco.cc/trials/xport-ec-042/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05611931>, <https://investors.karyopharm.com/2026-07-30-Karyopharm-Announces-Topline-Results-from-Phase-3-XPORT-EC-042-Trial-in-Endometrial-Cancer> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:subgroup" ;
  onco:phase "3" ;
  schema:startDate "2023-04-18" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/endometrial-nsmp/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/selinexor/> ;
  onco:companies <https://onco.cc/companies/karyopharm/> .